Q-omics provides the consensus-scored USH1C profile across patient tissues and cancer cell-line models. USH1C expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, USH1C is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, USH1C protein abundance shows 24,457 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, and PDAC as cancer lineages where USH1C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USH1C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USH1C survival associations across molecular data types. USH1C RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USH1C RNA expression–survival associations across cancer types. High USH1C expression shows unfavorable associations in LIHC, ACC and UVM, but favorable associations in KIRC, KIRP and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for USH1C RNA expression.
This table summarizes USH1C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for USH1C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USH1C shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, STAD, CHOL and LIHC. The KIRC box plot shows higher USH1C RNA expression in tumor versus normal tissue (log2 FC = +2.427, t-test p < 0.001).
This table shows molecular features associated with USH1C in patient tissues and cancer cell lines. In patient samples, USH1C shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, USH1C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
